Next Generation Diabetes Therapy and Drug Delivery - Global Strategic Business Report

The global market for Next Generation Diabetes Therapy and Drug Delivery was estimated at US$24.0 Billion in 2024 and is projected to reach US$34.1 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Next Generation Diabetes Therapy and Drug Delivery market.

Global Next Generation Diabetes Therapy and Drug Delivery Market - Key Trends & Drivers Summarized

Why Is the Landscape of Diabetes Therapy Undergoing a Transformation?

Next generation diabetes therapies are transforming how patients manage both Type 1 and Type 2 diabetes by offering more targeted, efficient, and user-friendly solutions. Traditional treatment approaches often involve multiple daily insulin injections or oral hypoglycemics with limited personalization. In contrast, the emerging therapeutic landscape focuses on precision delivery, patient-centric designs, and improved metabolic outcomes. Innovations are addressing persistent challenges such as hypoglycemia risk, therapy adherence, and glucose variability.

The growing global diabetes burden, coupled with long-term complications such as cardiovascular disease, neuropathy, and renal impairment, is intensifying demand for advanced therapies. Early intervention models, emphasis on glycemic control, and the shift toward home-based care are encouraging the adoption of next-generation systems. Patients are increasingly opting for integrated treatment solutions that combine convenience, real-time monitoring, and minimal invasiveness.

How Are Novel Drug Classes and Delivery Mechanisms Redefining Treatment Pathways?

Several new drug classes are expanding therapeutic options beyond insulin and metformin. GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists are now integral to Type 2 diabetes care due to their benefits in weight reduction, cardiovascular safety, and kidney protection. These agents are being delivered via weekly injectables, autoinjectors, and sustained-release implants that improve patient compliance and minimize side effects.

Delivery mechanisms are evolving rapidly, with insulin pumps, patch pumps, and smart pens gaining traction. Closed-loop systems, often termed artificial pancreas, combine continuous glucose monitoring with automated insulin delivery, allowing dynamic, algorithm-driven dosing adjustments. Microneedle arrays, inhalable insulin formulations, and oral peptide drugs are under development to eliminate injection-related barriers. These delivery innovations are enhancing therapeutic precision while promoting comfort and long-term adherence.

What Broader Healthcare Trends Are Supporting Technology Adoption in Diabetes Management?

Digital health integration is a major enabler of next-generation diabetes therapy. Connected insulin pens, mobile apps, and cloud-based platforms allow data sharing, trend tracking, and remote consultation. Patients and clinicians can now access real-time data for dose optimization and lifestyle adjustments, enhancing personalized care. Interoperability between monitoring devices and insulin delivery systems is improving usability, particularly for pediatric and elderly populations.

Healthcare systems are gradually adopting value-based care models, which emphasize outcome-driven interventions. This shift is encouraging use of therapies and devices that offer long-term benefits such as reduced hospitalization, improved quality of life, and prevention of complications. Growth in telemedicine and home health services is further supporting decentralization of diabetes care. Insurance reimbursement for advanced therapies and inclusion in national diabetes programs are helping accelerate adoption, especially in developed markets.

What Factors Are Driving Growth in the Next Generation Diabetes Therapy and Drug Delivery Market?

Growth in the next generation diabetes therapy and drug delivery market is driven by several factors. Rising global prevalence of diabetes is creating sustained need for innovative and efficient treatment models. Introduction of novel drug classes with extended half-lives and cardiometabolic benefits is reshaping pharmacological strategies. Advancements in smart delivery systems, including closed-loop pumps and wearable injectors, are improving control and patient autonomy. Digital integration and remote care enablement are enhancing treatment personalization and clinical oversight. Expansion of reimbursement coverage and regulatory support for integrated solutions are facilitating faster market entry and broader access. These trends are collectively redefining diabetes management, driving demand for advanced therapies and next-generation delivery technologies.

Scope Of Study:

The report analyzes the Next Generation Diabetes Therapy and Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas); Indication (Type 1 Diabetes, Type 2 Diabetes); End-Use (Diagnostics / Clinics End-Use, Intensive Care Units End-Use, Home Healthcare End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Inhalable Insulin segment, which is expected to reach US$13.9 Billion by 2030 with a CAGR of a 4.9%. The Oral Insulin segment is also set to grow at 7.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $6.3 Billion in 2024, and China, forecasted to grow at an impressive 6.0% CAGR to reach $5.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Next Generation Diabetes Therapy and Drug Delivery Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Next Generation Diabetes Therapy and Drug Delivery Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Next Generation Diabetes Therapy and Drug Delivery Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Beta Bionics, Inc., Camurus AB, Dexcom, Inc., Eli Lilly and Company and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 43 companies featured in this Next Generation Diabetes Therapy and Drug Delivery market report include:

• Abbott Laboratories
• Beta Bionics, Inc.
• Camurus AB
• Dexcom, Inc.
• Eli Lilly and Company
• Enteris BioPharma
• GlySens Incorporated
• Johnson & Johnson
• MannKind Corporation
• Medtech S.A.
• Medtronic plc
• Nemaura Medical Inc.
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Relmada Therapeutics
• Roche Holding AG
• Sanofi S.A.
• Senseonics Holding, Inc.
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Zosano Pharma Corp.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.